We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+24.49%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
+$415M
Cap. Flow
+$332K
Cap. Flow %
0.01%
Top 10 Hldgs %
37.9%
Holding
228
New
11
Increased
45
Reduced
33
Closed
6

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$17M
2
UNH icon
UnitedHealth
UNH
+$15.3M
3
CVS icon
CVS Health
CVS
+$14M
4
MRNA icon
Moderna
MRNA
+$13.1M
5
EXEL icon
Exelixis
EXEL
+$9.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$29.8M
2
AGN
Allergan plc
AGN
+$28M
3
GILD icon
Gilead Sciences
GILD
+$23.5M
4
ILMN icon
Illumina
ILMN
+$16.8M
5
CI icon
Cigna
CI
+$11.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TECX
151
Tectonic Therapeutic
TECX
$529M
$2.45M 0.09%
11,715
+5,475
+88% +$1.13M
ITCI
152
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.42M 0.09%
94,238
– –
DGX icon
153
Quest Diagnostics
DGX
$25.7B
$2.4M 0.09%
21,025
– –
NVAX icon
154
Novavax
NVAX
$1.2B
$2.38M 0.09%
28,550
– –
BHC icon
155
Bausch Health
BHC
$2.58B
$2.17M 0.08%
118,412
– –
ESPR
156
DELISTED
Esperion Therapeutics
ESPR
$2.13M 0.08%
41,577
– –
ALC icon
157
Alcon
ALC
$33.6B
$2.1M 0.08%
36,686
– –
RVNC
158
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.1M 0.08%
85,840
– –
ZYME icon
159
Zymeworks
ZYME
$1.61B
$2.02M 0.08%
55,938
+40,746
+268% +$1.5M
XRN
160
Chiron Real Estate Inc
XRN
$514M
$1.98M 0.08%
34,979
– –
PTLA
161
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.97M 0.07%
109,246
– –
CLLS
162
Cellectis
CLLS
$277M
$1.96M 0.07%
110,147
– –
HRTX icon
163
Heron Therapeutics
HRTX
$93.9M
$1.93M 0.07%
131,183
– –
AVDL
164
DELISTED
Avadel Pharmaceuticals
AVDL
$1.89M 0.07%
233,612
-332,454
-59% -$2.93M
HALO icon
165
Halozyme
HALO
$9.79B
$1.87M 0.07%
69,917
– –
HR icon
166
Healthcare Realty
HR
$7.28B
$1.87M 0.07%
70,662
– –
MYOK
167
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.86M 0.07%
19,300
– –
HOLX
168
DELISTED
Hologic
HOLX
$1.86M 0.07%
32,564
– –
INGN icon
169
Inogen
INGN
$175M
$1.83M 0.07%
51,406
– –
ENDP
170
DELISTED
Endo International plc
ENDP
$1.82M 0.07%
531,570
– –
MEDP icon
171
Medpace
MEDP
$16.1B
$1.75M 0.07%
18,871
– –
THC icon
172
Tenet Healthcare
THC
$20.5B
$1.75M 0.07%
96,736
– –
STE icon
173
Steris
STE
$22.3B
$1.72M 0.07%
11,218
– –
PACB icon
174
Pacific Biosciences
PACB
$435M
$1.71M 0.07%
495,495
– –
EVH icon
175
Evolent Health
EVH
$348M
$1.65M 0.06%
231,027
– –
5 6
7
8 9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Tekla Capital Management held 228 positions worth $2.63B, up 19% from $2.21B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tekla Capital Management's Q2 2020 filing shows 11 new, 45 increased, 33 reduced and 6 closed positions. Its largest new stake was Molina Healthcare: 27,536 shares worth $4.9M. The largest sale was Biogen, an estimated $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2020 buy was Molina Healthcare: 27,536 shares worth $4.9M.
  • Tekla Capital Management added most to AbbVie in Q2 2020, an estimated $17M increase.
  • Tekla Capital Management's biggest Q2 2020 reduction was Biogen, cutting an estimated $29.8M.
  • Tekla Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $28M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.63B portfolio in Q2 2020.
  • Tekla Capital Management opened 11 new positions and closed 6 in Q2 2020.
  • Tekla Capital Management's portfolio value rose 19% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.